Medical Technology Company Secures Neurostimulation Device Approval In Brazil

On June 17, 2024, Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW), a company known for its innovative neurostimulation products, announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency (ANVISA). ANVISA is a regulatory body under the Brazilian government responsible for the approval of new drugs and medical devices. This landmark approval marks a significant milestone for Nexalin Technology as it expands its reach into one of the largest markets in the world. $NEXALIN TECHNOLOGY INC C/WTS ( TO PUR COM ) (NXLIW.US)$